The FDA recently approved our personalized medicine for two different indications: ROS1-positive, metastatic non-small cell lung cancer and NTRK gene fusion-positive solid tumors.
?? of 40 moments published
Tell us what you think about our company, products, or website.
The way to do research is to attack the facts at the point of greatest astonishment.